Oncodesign Precision Medicine Logo

About Oncodesign Precision Medicine

Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's pipeline includes OPM-101, a potentially inhibitor of the RIPK2 target, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; OPM-102, a novel inhibitor that is in preclinical studies for the treatment of cancer; and OPM-201, a potential LRRK2 inhibitor, which is in Phase 1 clinical trial for the treatment of Parkinson's disease. It is also developing drugs for the treatment of pancreatic and other cancers. The company has a strategic collaboration agreement with Navigo Proteins GmbH for the discovery and development of new systemic radiotheranostic agents. Oncodesign Precision Medicine Société anonyme was founded in 1995 and is based in Dijon, France.